期刊文献+

十堰地区778例女性HPV的感染状况 被引量:1

Investigation of human papillomavirus infection in 778 women in Shiyan
原文传递
导出
摘要 目的分析本地区女性HPV感染现状,为预防HPV感染和宫颈癌提供理论依据。方法采用PCR-膜杂交法对本院门诊收治的778例女性患者进行21种HPV基因分型检测。结果共检测出289例HPV感染者,HPV感染率为37.15%,其中高危型感染占74.74%,低危型感染占17.65%,高、低危型混合感染占7.61%。高危型感染率最高的前5型别为HPV16(9.13%)、HPV58(7.46%)、HPV52(5.53%)、HPV33(3.60%)和HPV31(2.31%),低危型以HPV6(3.99%)和HPV11(2.31%)为主。HPV高危型感染率(30.59%)显著高于HPV低危型感染率(9.38%),差异具有统计学意义(χ2=707.152、P<0.001)。高危型多重感染率(21.34%)显著高于低危型多重感染率(2.00%),差异具有统计学意义(χ2=457.201、P<0.001)。在HPV阳性者中单纯感染228例(78.89%),多重感染61例(21.11%)。各年龄段HPV感染率差异无统计学意义(χ2=4.096、P=0.393),各年龄段感染类型均以高危型为主。结论高危型感染以HPV16、HPV52和HPV58为最常见型别,低危型感染以HPV6最常见。感染类型以单纯感染和高危型感染为主。多重感染以高危型和高、低混合型感染常见。该地区女性HPV感染情况与年龄无关。 Objective To investigate the infection of human papillomavirus (HPV) in local female patients and to provide valuable data for preventing HPV infection and cervical cancer occurrence. Methods Total of 21 types of HPV genotype were examined by PCR-Membrane hybridization technique in 778 women belonging to the outpatients of Shiyan Renmin Hospital. Results Among those 778 tested women there are 289 HPV positive patients and the infection rate was 37.15%. As for the proportion of HPV infection, 74.74%were high-risk HPV infections and 17.65% were low-risk HPV infections, while the other 7.61% were the combination of high-risk and low-risk HPV infections. The top five genotypes of high-risk HPV infection are HPV16 (9.126%), HPV58 (7.455%), HPV52 (5.527%), HPV33 (3.599%) and HPV31 (2.314%). And the main genotypes of low-risk HPV infection were HPV6 (3.985%) and HPV11 (2.314%). In this region, the infection rate of high-risk HPV (30.59%) was significantly higher than that of low-risk HPV (9.38%) (χ2 = 707.152, P 〈 0.001). And the infection rate of high-risk HPV multiple infection (21.34%) was also significantly higher compered with the infection rate of low-risk HPV multiple infection (2.00%) (χ2 = 457.201, P 〈 0.001). While the infection rates for the monotonous genotype of HPV infection and the multiple genotypes of HPV infection were 78.89% and 21.11%, respectively. And there is no significant difference between the infection rates of HPV in five age groups (χ2 = 4.096, P = 0.393). Totally high-risk HPV infection takes the majority of HVP infection in all groups. Conclusions HPV16, HPV52 and HPV58 were the most common genotypes of high-risk HPV infection, and HPV6 was the principal genotype of low-risk HPV infection. The main types of HPV infection was high-risk HPV infection and monotonous genotype of HPV infection. Multiple genotypes of HPV infections was mainly caused by high-risk HPV infection and high-risk and low-risk mixed HPV&amp;nbsp;infections. HPV infection in women in this region is independent of age.
作者 陈鹏 梁荣鑫 罗焰静 祝铖 李莲 Chen Peng;Liang Rongxin;LuoYanjing;Zhu Cheng;Li Lian(Department of Clinical Laboratory, Shiyan Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China;The First Clinical Medical School of Hubei University of Medicine, Shiyan 442000, China)
出处 《中华实验和临床感染病杂志(电子版)》 CAS 2017年第5期513-516,共4页 Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
关键词 人乳头瘤病毒感染 HPV基因型 宫颈癌 HPV infection HPV genotypes Cervical carcinoma
  • 相关文献

参考文献6

二级参考文献37

  • 1周毅.人类乳头瘤病毒与宫颈癌的相关调查[J].中华医院感染学杂志,2004,14(2):129-129. 被引量:16
  • 2黄庆,府伟灵,周玉,张雪,黄君富,陈斌.基因芯片对人乳头瘤病毒的快速检测和分型[J].中华医院感染学杂志,2005,15(4):476-478. 被引量:50
  • 3Kawana K, Yasugi T, Taketani Y. Human papillomavirus vaccines : current issues & future [ J ]. Indian J Med Res, 2009,130(3) :341-347.
  • 4Cid-Arregui A. Therapeutic vaccines against human papillomavirus and cervical cancer [ J ]. Open Virol J, 2009,3( 1 ) :67-83.
  • 5Harper DM. Currently approved prophylactic HPV vaccines [ J ]. Expert Rev Vaccines, 2009,8 ( 12 ) : 1663- 1679.
  • 6Rowhani-Rahbar A, Mao C,Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine [ J ]. Vaccine, 2009,27 (41) :5612-5619.
  • 7Mao C, Koutsky LA, Auh KA, et al. Efficacy of human papillomavims-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial [J]. Obstet Gynecol,2006,107( 1 ) :18-27.
  • 8Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus ( HPV ) -16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types ( PATRICIA ) : final analysis of a double-blind, randomised study in young women [ J ]. Lancet, 2009,374 (9686) : 301-314.
  • 9GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, et al. Sustained efiqcacy and immunogenicity of the human papillomavirus ( HPV )-16/18 AS04-adjuvanted vaccine : analysis of a randomised placebo-controlled trial up to 6.4 years [ J ]. Lancet ,2009,374(9706) : 1975-1985.
  • 10Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant [ J ]. J Adolesc Health, 2007,40 ( 6 ) : 564 -571.

共引文献70

同被引文献9

引证文献1

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部